Metformin (Met) reduces tumor-infiltrating Treg (Ti-Treg), especially in the terminally differentiated CD103+KLRG1+ population, and also reduces expression of immune suppressive effector molecules such as CTLA4 and IL-10. Here, IL10 is linked to neoplasm.